Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

The Lancet Oncology

Volumn 10, Issue 1, 2009, Pages 25-34

  Cheng, Ann Lii ^a   Kang, Yoon Koo ^b   Chen, Zhendong ^c   Tsao, Chao Jung ^d   Qin, Shukui ^e   Kim, Jun Suk ^f   Luo, Rongcheng ^g   Feng, Jifeng ^h   Ye, Shenglong ⁱ   Yang, Tsai Sheng ^j   Xu, Jianming ^k   Sun, Yan ^l   Liang, Houjie ^m   Liu, Jiwei ⁿ   Wang, Jiejun ^o   Tak, Won Young ^p   Pan, Hongming ^q   Burock, Karin ^r   Zou, Jessie ^s   Voliotis, Dimitris ^t   Guan, Zhongzhen ^u   more..

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Asan Medical Center   (South Korea)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d CHI MEI FOUNDATION HOSPITAL   (Taiwan)

^e Nanjing Bayi Hospital   (China)

^f Korea University College of Medicine   (South Korea)

^g FIRST MILITARY MEDICAL UNIVERSITY   (China)

^h JIANGSU CANCER HOSPITAL   (China)

ⁱ FUDAN UNIVERSITY   (China)

^j CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^k BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^l CANCER HOSPITAL   (China)

^m THIRD MILITARY MEDICAL UNIVERSITY   (China)

ⁿ DALIAN MEDICAL UNIVERSITY   (China)

^o SECOND MILITARY MEDICAL UNIVERSITY   (China)

^p Kyungpook National University Hospital   (South Korea)

^q ZHEJIANG UNIVERSITY   (China)

^r BAYER PHARMA AG   (Germany)

^s Bayer Schering Pharma   (China)

^t BAYER CORPORATION   (United States)

^u SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; ASCITES; ASIA; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTERACTIVE VOICE RESPONSE SYSTEM; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SOUTH KOREA; TAIWAN; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 57749189578     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70285-7     Document Type: Article

References (40)

1. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007) 2557-2576
2. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
3. McGlynn K.A., Tsao L., Hsing A.W., Devesa S.S., and Fraumeni Jr. J.F. International trends and patterns of primary liver cancer. Int J Cancer 94 (2001) 290-296
4. Kirk G.D., Lesi O.A., Mendy M., et al. The Gambia Liver Cancer Study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 39 (2004) 211-219
5. Hung H. Treatment modalities for hepatocellular carcinoma. Curr Cancer Drug Targets 5 (2005) 131-138
6. Lopez P.M., Villanueva A., and Llovet J.M. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 23 (2006) 1535-1547
7. Llovet J.M. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40 (2005) 225-235
8. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
9. Umemura T., and Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 37 suppl 2 (2007) S95-100
10. Makuuchi M., and Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J Gastroenterol 12 (2006) 828-829
11. Park J.W. [Practice guideline for diagnosis and treatment of hepatocellular carcinoma]. Korean J Hepatol 10 (2004) 88-98
12. Llovet J.M., Bustamante J., Castells A., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29 (1999) 62-67
13. Yeung Y.P., Lo C.M., Liu C.L., Wong B.C., Fan S.T., and Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 100 (2005) 1995-2004
14. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28 (1998) 751-755
15. Hwang Y.H., Choi J.Y., Kim S., et al. Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 29 (2004) 113-121
16. Avila M.A., Berasain C., Sangro B., and Prieto J. New therapies for hepatocellular carcinoma. Oncogene 25 (2006) 3866-3884
17. de La Coste A., Romagnolo B., Billuart P., et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95 (1998) 8847-8851
18. Carlomagno F., Anaganti S., Guida T., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98 (2006) 326-334
19. Wilhelm S., Carter C., Lynch M., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5 (2006) 835-844
20. Huynh H., Nguyen T.T., Chow K.H., Tan P.H., Soo K.C., and Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol 3 (2003) 19
21. Yoshida T., Hisamoto T., Akiba J., et al. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 25 (2006) 6056-6066
22. Poon R.T., Lau C., Pang R., Ng K.K., Yuen J., and Fan S.T. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 14 (2007) 1835-1845
23. Wada H., Nagano H., Yamamoto H., et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int 26 (2006) 414-423
24. Stock P., Monga D., Tan X., Micsenyi A., Loizos N., and Monga S.P. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 6 (2007) 1932-1941
25. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008) 378-390
26. Pugh R.N., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., and Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 (1973) 646-649
27. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
28. NCI. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (2006). http://ctep.cancer.gov/forms/CTCAEv3.pdf (accessed Dec 2, 2008).
29. Porta C., Paglino C., Imarisio I., and Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 7 (2007) 127-134
30. Chu D., Lacouture M.E., Fillos T., and Wu S. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 47 (2008) 176-186
31. Cantarini M.C., Trevisani F., Morselli-Labate A.M., et al. Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol 101 (2006) 91-98
32. Furuse J., Ishii H., Nakachi K., Suzuki E., Shimizu S., and Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99 (2008) 159-165
33. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 4293-4300
34. Guan Z., Kang Y., Chen Z., et al. Sorafenib is effective in hepatitis B-positive patients with hepatocellular carcinoma: subgroup analysis of a randomized, double-blind, phase III trial performed in the Asia-Pacific region. Ann Oncol 19 suppl 8 (2008) viii166-viii186
35. Huitzil-Melendez F.D., Saltz L.B., Song J., et al. Retrospective analysis of outcome in hepatocellular carcinoma patients with hepatitis C versus B treated with sorafenib. Proc Am Soc Clin Oncol Gastrointest Cancer Symp (2007) abstr 173.
36. de Villa V., and Lo C.M. Liver transplantation for hepatocellular carcinoma in Asia. Oncologist 12 (2007) 1321-1331
37. Muszbek N., Shah S., Carroll S., et al. Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. Curr Med Res Opin 24 (2008) 3559-3569
38. Muszbek N., Shah S., Carroll S., Carr B., and Gondek K. Economic evaluation of sorafenib vs. best supportive care in hepatocellular carcinoma. Proc Am Soc Clin Oncol 26 suppl (2008) abstr 6527.
39. Nadler E., Eckert B., and Neumann P.J. Do oncologists believe new cancer drugs offer good value?. Oncologist 11 (2006) 90-95
40. Braithwaite R.S., Meltzer D.O., King Jr. J.T., Leslie D., and Roberts M.S. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?. Med Care 46 (2008) 349-356